Mumbai: Pharma Major, Glenmark Pharmaceuticals announced a presentation of preliminary biomarker findings from a Phase 1 study of GBR 1302 (NCT02829372), an investigational bispecific antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco.
GBR 1302 is based on Glenmark’s proprietary BEAT platform and simultaneously targets HER2 and the CD3 T cell co-receptor. HER2 is overexpressed in a variety of solid tumours and is a validated therapeutic target, the company said in filing with BSE.
This first-in-human study is ongoing and enrolling adults with progressive HER2-positive solid tumours who have not responded to available treatment options. The study is evaluating the safety and tolerability of GBR 1302 and exploring its anti-tumor activity.
“The discovery of agents targeting HER2 has greatly improved the treatment of a variety of cancers where it is overexpressed,” said Kurt Stoeckli, President and Chief Scientific Officer at Glenmark Pharmaceuticals.
“Investigational treatments like bispecific antibodies that target a broad spectrum of HER2 expression levels on a variety of tumour tissues while simultaneously engaging tumour-infiltrating T cells have the potential to advance the treatment of these tumours, and may fulfill a substantial unmet medical need. We are pleased to share this early data characterizing the clinical activity of GBR 1302 at the ASCO-SITC symposium.”